Aadi Bioscience, Inc. (AADI) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
August 10, 2022 8:00 AM EDTFYARRO® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022
PRECISION 1 Phase 2 tumor-agnostic registration-directed trial continues enrollment and rapid site activation at major cancer centers and large community networks; preliminary data expected 1H23
Conference call to be held today at 8:30 am EDT
LOS ANGELES, Aug. 10, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for... More



